Product Pipeline

This list contains information about the development status of unapproved drugs or unapproved indications. Nothing herein are intended to constitute promotion or advertisement of pharmaceutical products (including products currently in development).

IND Code Dosage Form Features Indications Development
Locations		 Development
Stage
TAS-115 Oral Multi-kinase inhibitor Prostate cancer Japan Phase II
Chronic Fibrosing Interstitial Lung
with a Progressive Phenotype		 Japan Phase II
Osteosarcoma Japan Phase III
TAS-116 Oral HSP90 inhibitor Solid tumors US Phase I
Europe Phase I
Prostate cancer Japan Phase II
TAS-117 Oral AKT inhibitor Solid tumors with germline PTEN
mutations		 Japan Phase II
US Phase II
Europe Phase II
TAS-120
 Oral FGFR inhibitor　 Breast cancer US Phase II
Europe Phase II
FGFR aberrations cancer Japan Phase II
US Phase II
Europe Phase II
Urothelial cancer US Phase II
Europe Phase II
TAS0313 Injection Peptide vaccine Urothelial cancer Japan Phase II
TAS0728 Oral 　 Solid tumors US Phase I/II
Europe Phase I/II
TAS0612 Oral Solid tumors US

Phase I
Europe Phase I
TAS0953 Oral Solid tumors Japan Phase I/II
TAS2940 Oral Solid tumors US Phase I/II
Europe Phase I
TAS6417 Oral EGFR inhibitor Non-small cell lung cancer Japan Phase I/II
US Phase I/II
Europe Phase I/II
TAS3351 Oral Non-small cell lung cancer Japan Phase I/II
US Phase I/II
Europe Phase I/II
ET-743 Injection Ovarian cancer Japan Phase I
AB122 Injection Solid tumors Japan Phase I
AB122+TAS-116 Injection + oral Solid tumors Japan Phase I
AB122+TAS-115 Injection + oral Solid tumors Japan Phase I
AB122+TAS-120 Injection + oral Solid tumors Japan Phase I
AB122＋AB154 Injection Anti-PD-1 antibody
＋Anti-TIGIT antibody		 Non-small cell lung cancer Japan Phase I
Upper gastrointestinal cancer Japan Phase III
TAS-205 Oral PGD synthase inhibitor Duchenne muscular dystrophy
(DMD)		 Japan Phase III
TAS5315 Oral BTK inhibitor Rheumatoid arthritis(RA) Japan Phase II
Chronic spontaneous urticaria Japan Phase II
TAC-302 Oral 　 Detrusor underactivity with
overactive bladder		 Japan Phase II
TAS-303 Oral Selective noradrenaline
reuptake inhibitor		 Stress urinary incontinence Japan Phase II

As of Oct. 31, 2023